Abstract 3779
Background
HER2-gene mutations are considered to be an important prognostic factor in patients with lung cancer. The aim of our study was to assess the frequency and significance of HER2-gene single nucleotide polymorphisms -1985G>T and P1170AC>G among the patients with small-cell and non-small cell lung cancer and to compare this data to healthy subjects.
Methods
The study was performed among 359 patients (69% males and 31% females; mean age of 59.96 ± 18.24 years) with diagnosis of stage IV small-cell (24.6% of patients) and non-small cell lung cancer (75.4% of patients) compared to 167 healthy subjects (72% males and 28% females; mean age of 69.96 ± 11.74 years). The frequencies of two polymorphisms of the HER-2-gene -1985G>T and P1170A C>G were detected using the quantitative real-time polymerase chain reaction (qRT-PCR) restriction fragment length polymorphism (RFLP) assay. The study was conducted according to the Declaration of Helsinki, the protocol was reviewed and approved by the institutional Ethics committee and all patients provided written informed consent.
Results
We found statistically significant difference in the distribution of genetic mutation variants -1985G>T and P1170A C>G among the patients with lung adenocarcinoma compared to healthy subjects (p < 0.001). The -1985G>T and P1170A C>G allelic variants were not significantly expressed among the patient and control groups in overall subject (p = 0.874).
Conclusions
Our study indicates that the expressions of genetic variants -1985G>T and P1170A C>G is associated with higher risk of development of lung adenocarcinoma. There was no statistical difference among patient and control groups in overall subjects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4228 - Clinical Evaluation of Drug-Eluting Bead Transcatheter Arterial Chemoembolization(D-TACE) versus Conventional TACE in Treatment of unresectable Hepatocellular Carcinoma
Presenter: Yi Chen
Session: Poster Display session 1
Resources:
Abstract
3930 - Safety profile of tepotinib in patients with advanced solid tumors: pooled analysis of phase I and II data
Presenter: Thomas Decaens
Session: Poster Display session 1
Resources:
Abstract
5373 - Drug-drug interaction profile of tepotinib with CYP3A and P-gp substrates
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
5455 - Bioavailability of tepotinib: impact of omeprazole and food
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
2618 - Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2563 - Population Pharmacokinetics of Tislelizumab in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2021 - The Addition of Metformin to Systemic Anticancer Therapy
Presenter: Jung Han Kim
Session: Poster Display session 1
Resources:
Abstract
5243 - Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients
Presenter: Antoine Italiano
Session: Poster Display session 1
Resources:
Abstract
598 - Analysis of the overall survival and main surrogates used for FDA approvals in solid and hematological malignancies.
Presenter: Maria Kleniewska-Wieczor
Session: Poster Display session 1
Resources:
Abstract
5381 - Comparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): the CriTax study
Presenter: Ruben Van Eerden
Session: Poster Display session 1
Resources:
Abstract